A 71-year-old female with type 2 diabetes mellitus, weight 74 kg, normal creatinine, moderately reduced estimated glomerular filtration rate, elevated anion gap, low bicarbonate, severe hyperglycemia, elevated serum ketones, mild acidosis, high serum osmolality, history of pancreatitis, currently taking glipizide only, and hemoglobin A1c rising from 6.8% to 13.1%—what is the appropriate management?

Immediate Management: This Patient Has Diabetic Ketoacidosis and Requires Hospitalization with IV Insulin Therapy

This 71-year-old woman meets criteria for diabetic ketoacidosis (DKA) and requires immediate hospital admission with continuous IV insulin infusion, aggressive fluid resuscitation, and electrolyte monitoring—glipizide must be discontinued immediately. 1

Why This Is DKA

Your patient has the diagnostic triad:

• Hyperglycemia: Blood glucose 460 mg/dL (>250 mg/dL threshold)
• Ketosis: Serum ketones 5.23 mmol/L (significantly elevated)
• Metabolic acidosis: pH 7.35 (borderline), bicarbonate 22 mmol/L (low-normal), elevated anion gap 20

While the pH of 7.35 is at the lower limit of normal, the combination of severe hyperglycemia, marked ketonemia (>3 mmol/L is significant), elevated anion gap, and low-normal bicarbonate indicates evolving or partially compensated DKA. The elevated osmolality (315 mOsm/kg) adds a hyperosmolar component. 2

Critical First Steps

1. Discontinue Glipizide Immediately

• Sulfonylureas are contraindicated in acute hyperglycemic crises 3
• The FDA label explicitly states: "When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of control may occur. At such times, it may be necessary to discontinue glipizide and administer insulin" 3
• Glipizide increases hypoglycemia risk during treatment and provides no benefit in DKA management

2. Hospitalize for IV Insulin Therapy

Continuous insulin infusion is the preferred regimen for hyperglycemic crises 1. The guideline is clear: patients with moderate-to-severe DKA should receive continuous IV insulin, though mild-to-moderate cases may be treated with frequent subcutaneous insulin 1.

Given her:

• Ketones >5 mmol/L (severe ketonemia)
• Borderline acidosis with high anion gap
• Age 71 with reduced GFR (61 mL/min)
• Severe hyperglycemia (460 mg/dL)

She requires inpatient continuous insulin infusion to safely reverse ketoacid production.

3. Aggressive Fluid Resuscitation

• DKA causes profound dehydration through osmotic diuresis
• IV fluid replacement is essential before and during insulin therapy
• Monitor closely given her age and reduced GFR

4. Potassium Monitoring and Replacement

This is critical: Hypokalaemia occurs in ~50% of DKA cases during treatment and severe hypokalaemia (<2.5 mEq/L) is associated with increased mortality 1.

• Check potassium before starting insulin
• If K+ <3.3 mEq/L: hold insulin and replace potassium first
• If K+ 3.3-5.3 mEq/L: start insulin AND potassium replacement simultaneously
• Monitor potassium every 2-4 hours initially

5. Identify the Precipitant

The dramatic A1c rise from 6.8% to 13.1% over one year indicates:

• Severe treatment failure on glipizide monotherapy
• Possible undiagnosed illness (infection, MI, pancreatitis recurrence)
• Medication non-adherence (though A1c suggests chronic poor control)

Search for: infection (most common precipitant), cardiac ischemia, medication changes, or pancreatitis recurrence given her history 2.

Transition Planning

Once stabilized (normal anion gap, pH >7.3, able to eat):

Calculate Subcutaneous Insulin Needs

• Average the insulin infusion rate over the last 12 hours before transition
• Example: If receiving 1.5 units/hour → 36 units/24 hours total daily dose
• Split into basal (50%) and prandial (50%) insulin 1

Do NOT Restart Glipizide

With A1c 13.1%, she has failed oral monotherapy. Options:

• Basal-bolus insulin regimen (most appropriate given severity)
• Consider adding metformin if no contraindications (GFR 61 is acceptable)
• SGLT2 inhibitors are relatively contraindicated given her DKA presentation and pancreatitis history

Discharge Requirements

Per Endocrine Society guidelines 4:

• Initiate final insulin regimen at least 1 day before discharge to assess safety and efficacy
• Provide written and oral instructions on insulin administration, timing, and doses
• Teach hypoglycemia recognition and treatment
• Arrange endocrinology follow-up within 1-2 weeks
• Provide glucose monitoring supplies and log book

Common Pitfalls to Avoid

1. Don't be fooled by "borderline" pH: The combination of severe ketonemia (5.23 mmol/L) with elevated anion gap and hyperglycemia IS DKA, even if pH hasn't dropped to <7.3 yet
2. Don't continue glipizide: It's contraindicated in acute illness and provides no benefit 3
3. Don't forget potassium: Start monitoring and replacement early—waiting for hypokalemia to develop can be fatal 1
4. Don't discharge on glipizide alone: She has clearly failed this therapy (A1c 6.8%→13.1%)
5. Don't transition to subcutaneous insulin too early: Wait for anion gap normalization, not just glucose normalization 1

Why Outpatient Management Is Inappropriate

Even though her pH is 7.35, outpatient management would be dangerous because:

• Ketones 5.23 mmol/L require continuous monitoring during reversal
• Risk of severe hypokalaemia during treatment
• Age 71 with reduced GFR increases complication risk
• Need to identify precipitating cause
• Requires insulin education before safe discharge

Admit her now for IV insulin therapy, aggressive hydration, and electrolyte management.